cefuroxime has been researched along with Innate Inflammatory Response in 4 studies
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report cases of intraocular inflammation after intracameral injection of a very high dose of cefuroxime at the end of uneventful cataract surgery." | 3.77 | Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery. ( Colin, J; Dalbon, F; Delyfer, MN; Korobelnik, JF; Leoni, S; Rougier, MB; Zhang, Q, 2011) |
| "Cefuroxime was chosen as the PBP-3-active antibiotic and tobramycin represented the aminoglycosides." | 1.56 | Mode of bacterial killing affects the inflammatory response and associated organ dysfunctions in a porcine E. coli intensive care sepsis model. ( Larsson, A; Lipcsey, M; Maudsdotter, L; Sjölin, J; Skorup, P, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Skorup, P | 2 |
| Maudsdotter, L | 2 |
| Lipcsey, M | 2 |
| Larsson, A | 2 |
| Sjölin, J | 2 |
| Jensen, LK | 1 |
| Koch, J | 1 |
| Henriksen, NL | 1 |
| Bue, M | 1 |
| Tøttrup, M | 1 |
| Hanberg, P | 1 |
| Søballe, K | 1 |
| Jensen, HE | 1 |
| Tano, E | 1 |
| Castegren, M | 1 |
| Delyfer, MN | 1 |
| Rougier, MB | 1 |
| Leoni, S | 1 |
| Zhang, Q | 1 |
| Dalbon, F | 1 |
| Colin, J | 1 |
| Korobelnik, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU[NCT05511129] | 1,053 participants (Actual) | Observational | 2022-05-12 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for cefuroxime and Innate Inflammatory Response
| Article | Year |
|---|---|
Mode of bacterial killing affects the inflammatory response and associated organ dysfunctions in a porcine E. coli intensive care sepsis model.
Topics: Animals; Cefuroxime; Disease Models, Animal; Endotoxins; Escherichia coli; Escherichia coli Infectio | 2020 |
Suppurative Inflammation and Local Tissue Destruction Reduce the Penetration of Cefuroxime to Infected Bone Implant Cavities.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Inflammation; Osteomyelitis; Prostheses and Implants; Pr | 2017 |
Dynamics of Endotoxin, Inflammatory Variables, and Organ Dysfunction After Treatment With Antibiotics in an Escherichia coli Porcine Intensive Care Sepsis Model.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Disease Models, Animal; Drug Therapy, Combination; Endot | 2018 |
Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery.
Topics: Aged; Aged, 80 and over; Anterior Eye Segment; Anti-Bacterial Agents; Cataract Extraction; Cefuroxim | 2011 |